QT-prolonging medications: prevalence of use and associated risks in CKD

Area of Science:

• Nephrology
• Cardiology
• Clinical Pharmacology

Background:

• Chronic kidney disease (CKD) affects over 10% of adults globally, contributing to significant cardiovascular issues.
• Sudden cardiac death, often due to ventricular arrhythmias like torsades de pointes, is a major cause of mortality in CKD patients.
• QT interval prolongation, indicating delayed ventricular repolarization, is a key risk factor for arrhythmias in CKD patients, on or off dialysis.

Purpose of the Study:

• To critically evaluate the pathophysiological relevance of QT-prolonging drug use in CKD.
• To assess the prevalence and cardiovascular consequences of these drugs in CKD patients.
• To review the safety data of commonly prescribed QT-prolonging medications in this vulnerable population.

Main Methods:

• Narrative review of existing literature.
• Analysis of pharmaco-epidemiological studies using the United States Renal Data System.
• Evaluation of pathophysiological mechanisms contributing to QT prolongation in CKD.

Main Results:

• QT prolongation in CKD is multifactorial, involving electrolyte shifts, cardiac remodeling, autonomic dysfunction, and drug exposure.
• Patients on hemodialysis are particularly susceptible due to rapid fluid and electrolyte changes.
• Pharmaco-epidemiological studies link QT-prolonging drugs to increased sudden cardiac death risk in dialysis patients.

Conclusions:

• Widespread use of QT-prolonging drugs in CKD patients, despite limited safety data, is a significant concern.
• These medications are associated with an elevated risk of sudden cardiac death in CKD, particularly in those on dialysis.
• Further research and cautious prescribing are warranted to mitigate cardiovascular risks in CKD patients using these drugs.